AMAG Pharmaceuticals Stock News

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)’s stock price shot up 7.2% during mid-day trading on Tuesday . The company traded as high as $5.36 and last traded at $5.23, 942,706 shares changed hands dur

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ...

Charles Schwab Investment Management Inc. boosted its holdings in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced eff

Panagora Asset Management Inc. lowered its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 44.2% in the fourth quarter, according to the company in its most recent disclosure with th

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dum

Q4 2019 AMAG Pharmaceuticals Inc Earnings Call

Q4 2019 AMAG Pharmaceuticals Inc Earnings Call

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)’s stock price fell 6% during mid-day trading on Monday . The company traded as low as $7.00 and last traded at $7.22, 997,071 shares were traded during mid-d

AMAG Pharmaceuticals (NASDAQ:AMAG)‘s stock had its “buy” rating reiterated by equities research analysts at Barclays in a research note issued on Sunday, AnalystRatings.com reports. They present

AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.